Found: 22
Select item for more details and to access through your institution.
Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group.
- Published in:
- Journal of Oncology Pharmacy Practice, 2024, v. 30, n. 7, p. 1144, doi. 10.1177/10781552231203371
- By:
- Publication type:
- Article
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 4, p. 536, doi. 10.1111/bjh.15679
- By:
- Publication type:
- Article
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 6, p. 831, doi. 10.1111/bjh.15092
- By:
- Publication type:
- Article
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 5, p. 783, doi. 10.1111/bjh.14483
- By:
- Publication type:
- Article
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A Stepwise Screening Protocol for Multiple Myeloma.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 4, p. 1345, doi. 10.3390/jcm12041345
- By:
- Publication type:
- Article
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 23, p. 5504, doi. 10.3390/jcm10235504
- By:
- Publication type:
- Article
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
- Published in:
- European Journal of Haematology, 2019, v. 102, n. 6, p. 494, doi. 10.1111/ejh.13231
- By:
- Publication type:
- Article
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a “real‐world” study: Polish Myeloma Group experience.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 3, p. 354, doi. 10.1111/ejh.13106
- By:
- Publication type:
- Article
An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S333, doi. 10.1016/j.clml.2017.07.148
- By:
- Publication type:
- Article
Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e131, doi. 10.1016/j.clml.2017.03.237
- By:
- Publication type:
- Article
Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.
- Published in:
- European Journal of Clinical Pharmacology, 2006, v. 62, n. 4, p. 325, doi. 10.1007/s00228-006-0106-2
- By:
- Publication type:
- Article
Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survival.
- Published in:
- International Journal of Cancer, 2021, v. 148, n. 8, p. 1887, doi. 10.1002/ijc.33377
- By:
- Publication type:
- Article
Therapy-related peripheral neuropathy in multiple myeloma patients.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
- Published in:
- Hematological Oncology, 2013, v. 31, n. 1, p. 41, doi. 10.1002/hon.2018
- By:
- Publication type:
- Article
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 5, p. 503, doi. 10.1002/ajh.25758
- By:
- Publication type:
- Article
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 6, p. 575, doi. 10.1002/ajh.24351
- By:
- Publication type:
- Article
Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 2, p. 411, doi. 10.3390/cells10020411
- By:
- Publication type:
- Article
High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.
- Published in:
- Oncology Letters, 2019, v. 18, n. 6, p. 5811, doi. 10.3892/ol.2019.10929
- By:
- Publication type:
- Article
Acute T Cell Lymphoblastic Leukemia in the Recipient of a Renal Transplant from a Donor with Malignant Lymphoma.
- Published in:
- Acta Haematologica, 2008, v. 119, n. 3, p. 187, doi. 10.1159/000137944
- By:
- Publication type:
- Article
<sup>18</sup>F-fluoro-ethyl-tyrosine (<sup>18</sup>F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study.
- Published in:
- Contemporary Oncology / Współczesna Onkologia, 2019, v. 23, n. 1, p. 23, doi. 10.5114/wo.2019.83342
- By:
- Publication type:
- Article
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
- Published in:
- EJHaem, 2024, v. 5, n. 5, p. 940, doi. 10.1002/jha2.968
- By:
- Publication type:
- Article